NCE-1 Intelligence & Market Opportunity

Voxzogo

Vosoritide

Musculoskeletal agent

Subcutaneous Powder

Approval Date

19-Nov-21

NCE-1 Date

19-Nov-25

NCE Date

19-Nov-26

Commercial snapshot

Market performance & projections

Revenue ($M)

927

CAGR (%)

0.0556

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

1002

2027

1095

2028

1128

2029

1151

2030

1161

2031

1190

2032

1241

Molecule profile

Details & specifications

Molecule

Vosoritide

Innovator

BIOMARIN PHARMACEUTICAL INC.

Dosage Form

Subcutaneous Powder

Strength

0.56 mg/vial, 1.2 mg/vial, 0.4 mg/vial

Therapeutic Category

Musculoskeletal agent

Usage

To improve growth in children five years of age and older with achondroplasia and open epiphyses

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.